Childhood disorders of neurodegeneration with brain iron accumulation (NBIA)

Developmental Medicine and Child Neurology

Volumn 53, Issue 5, 2011, Pages 394-404

  Kurian, Manju A ^a   Mcneill, Alasdair ^b   Lin, Jean Pierre ^c   Maher, Eamonn R ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; PHOSPHOLIPID;

AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; CELL FUNCTION; CHILDHOOD DISEASE; CLINICAL FEATURE; FATTY ACID METABOLISM; GENE; GENE MUTATION; HUMAN; NERVE DEGENERATION; NEUROAXONAL DYSTROPHY; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; PANK2 GENE; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PHENOTYPE; PHOSPHOLIPASE A2 GROUP 6 ASSOCIATED NEURODEGENERATION; PLA2G6 GENE; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; BRAIN; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; FEMALE; HUMANS; INFANT; IRON; MAGNETIC RESONANCE IMAGING; MALE; NERVE DEGENERATION; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; YOUNG ADULT;

EID: 79954460490     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2011.03955.x     Document Type: Review

References (57)

1. Gelman N, Gorell JM, Barker PB, et al. MR imaging of human brain at 3.0T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999; 210: 759-67.
2. Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006; 70: 133-42.
3. House MJ, St Pierre TG, Kowdley KV, et al. Correlation of proton transverse relaxation rates (R2) with iron concentrations in post-mortem brain tissue from Alzheimer's disease patients. Magn Reson Med 2007; 57: 172-80.
4. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28: 350-4.
5. Burn J, Chinnery PF. Neuroferritinopathy. Semin Pediatr Neurol 2006; 13: 176-81.
6. Yoshida K, Furihata K, Takeda S, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 267-72.
7. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60: 200-5.
8. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010; 25: 979-84.
9. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009; 46: 73-80.
10. * and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70: 1614-9.
11. Kurian MA, Morgan NV, MacPherson L, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70: 1623-9.
12. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345-9.
13. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006; 38: 752-4.
14. Hartig MB, Iuso A, Hempel M, et al. Identification of a second major locus for neurodegeneration with brain iron accumulation. American Society of Human Genetics 59th Annual Meeting, Honolulu, 20-24th October 2009. Available at .
15. Kruer MC, Paisán-Ruiz C, Boddaert N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010; 68: 611-8.
16. Khateeb S, Flusser H, Ofir R, et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 2006; 79: 942-8.
17. Balsinde J, Balboa MA. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 2005; 17: 1052-62.
18. Tanaka H, Minakami R, Kayana H, Sumimoto H. Catalytic residues of group VIB calcium-independent phospholipase A2 (iPLA2gamma). Biochem Biophys Res Commun 2004; 320: 1284-90.
19. Wada H, Yasuda T, Miura I, et al. Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. Am J Pathol 2009; 175: 2257-63.
20. Shinzawa K, Sumi H, Ikawa M, et al. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci 2008; 28: 2212-20.
21. Malik I, Turk J, Mancuso DJ, et al. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol 2008; 172: 406-16.
22. Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71: 1402-9.
23. Crompton D, Rehal PK, Macpherson L, et al. Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis. Mol Genet Metab 2010; 100: 207-12.
24. Hayflick SJ. Dystonia-parkinsonism disease gene discovery: expect surprises. Ann Neurol 2009; 65: 2-3.
25. Seven M, Ozkilic A, Yuksel A. Dysmorphic face in two siblings with infantile neuroaxonal dystrophy. Genet Couns 2002; 13: 465-73.
26. Aicardi J, Castelein P. Infantile neuroaxonal dystrophy. Brain 1979; 102: 727-48.
27. Nardocci N, Zorzi G, Farina L, et al. Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. Neurology 1999; 52: 1472-8.
28. Scheithauer BW, Forno LS, Dorfman LJ, Kane CA. Neuroaxonal dystrophy (Seitelberger's disease) with late onset, protracted course and myoclonic epilepsy. J Neurol Sci 1978; 36: 247-58.
29. Barontini F, Papini M. Late infantile neuroaxonal dystrophy. An unusual case with predominantly myoclonic-epileptic symptomatology. Riv Patol Nerv Ment 1981; 101: 171-84.
30. Wu Y, Jiang Y, Gao Z, et al. Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. Eur J Neurol 2009; 16: 240-5.
31. Farina L, Nardocci N, Bruzzone MGL, et al. Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients. Neuroradiology 1999; 41: 376-80.
32. Tanabe Y, Iai M, Ishii M, et al. The use of magnetic resonance imaging in diagnosing infantile neuroaxonal dystrophy. Neurology 1993; 43: 110-3.
33. Biancheri R, Rossi A, Alpigiani G, et al. Cerebellar atrophy without cerebellar cortex hyperintensity in infantile neuroaxonal dystrophy (INAD) due to PLA2G6 mutation. Eur J Paediatr Neurol 2007; 11: 175-7.
34. Carrilho I, Santos M, Guimarães A, et al. Infantile neuroaxonal dystrophy: what's most important for the diagnosis? Eur J Paediatr Neurol 2008; 12: 491-500.
35. Mubaidin A, Roberts E, Hampshire D, et al. Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J Med Genet 2003; 40: 543-6.
36. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65: 19-23.
37. Sina F, Shojaee S, Elahi E, Paisán-Ruiz C. R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. Eur J Neurol 2009; 16: 1-4.
38. Johnson MA, Kuo YM, Westaway SK, et al. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci 2004; 1012: 282-98.
39. Yang Y, Wu Z, Kuo YM, Zhuo B. Dietary rescue of fumble - a Drosophila model for pantothenate-kinase-associated neurodegeneration. J Inherit Metab Dis 2005; 28: 1055-64.
40. Kuo YM, Duncan JL, Westaway SK, et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum Mol Genet 2005; 14: 49-57.
41. Kuo YM, Hayflick SJ, Gitshier J. Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. J Inherit Metab Dis 2007; 30: 310-7.
42. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervordern-Spatz syndrome. N Engl J Med 2003; 348: 33-40.
43. Pellechia MT, Valente EM, Cif L, et al. The diverse phenotype and genotype of pantothenate-kinase associated neurodegeneration. Neurology 2005; 64: 1810-2.
44. Hartig MB, Hortnagel K, Garavaglia B, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006; 59: 248-56.
45. Freeman K, Gregory A, Turner A, et al. Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 2007; 51: 417-26.
46. Molinuevo JL, Marti MJ, Blesa R, Tolosa E. Pure akinesia: an unusual phenotype of Hallervorden-Spatz syndrome. Mov Disord 2003; 18: 1351-3.
47. Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with pantothenate kinase associated neurodegeneration. Neurology 2002; 58: 1673-4.
48. Kumar N, Boes CJ, Babovic-Vuksanovic D, Boeve BF. The 'eye-of-the-tiger' sign is not pathognomonic of the PANK2 mutation. Arch Neurol 2006; 63: 292-3.
49. Zolkipli Z, Dahmoush H, Saunders DE, Chong WK, Surtees R. Pantothenate kinase 2 mutation with classic pantothenate-kinase-associated neurodegeneration without 'eye-of-the-tiger' sign on MRI in a pair of siblings. Pediatr Radiol 2006; 36: 884-6.
50. Streker K, Hesse S, Wegner F, et al. Eye of the Tiger sign in multiple systems atrophy. Eur J Neurol 2007; 14: e1-2.
51. Egan RA, Weleber RG, Hogarth P, et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol 2005; 140: 267-74.
52. Dick KJ, Eckhardt M, Paisán-Ruiz C, et al. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat 2010; 31: E1251-60.
53. Edvardson S, Hama H, Shaag A, et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet 2008; 83: 643-8.
54. Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005; 57: 738-41.
55. Isaac C, Wright I, Bhattacharyya D, Baxter P, Rowe J. Pallidal stimulation for pantothenate kinase associated neurodegeneration. Arch Dis Child 2008; 93: 239-40.
56. Timmermann L, Pauls KA, Wieland K, et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010; 133: 701-12.
57. Mahoney R, Selway R, Lin J-P. Cognitive functioning in children with pantothenate-kinase-associated-neurodegeneration undergoing deep brain stimulation. Dev Med Child Neurol 2011; 53: 275-9.